Literature DB >> 19088323

Effect of molecules secreted by Lactobacillus acidophilus strain La-5 on Escherichia coli O157:H7 colonization.

Maira J Medellin-Peña1, Mansel W Griffiths.   

Abstract

The probiotic bacterium Lactobacillus acidophilus strain La-5 is a gut-colonizing microorganism that, when established, becomes an important part of the gastrointestinal (GI) tract microbiota. It has been shown to be effective against enterohemorrhagic Escherichia coli (EHEC) O157:H7 infection. We have previously shown that molecules released by probiotic strain La-5 influence the transcription of EHEC genes involved in colonization and quorum sensing. In this work, we report on the ability of these molecules to prevent the adherence of EHEC to epithelial cells and on its capacity to concentrate F-actin at adhesion sites. With a fluorescein-labeled phallotoxin, it was shown that La-5 cell-free spent medium (CFSM) fractions remarkably reduced attaching and effacing lesions in HeLa cells. We also observed a significant inhibition of bacterial adhesion to Hep-2 cells when they were treated with the same La-5 CFSM fractions. In order to observe if La-5 CFSM fractions exhibited the same effect in vivo, we studied the ability of luminescent EHEC constructs (LEE1::luxCDABE) to adhere to intestinal epithelial cells of specific-pathogen-free ICR mice following intragastric inoculation. Colonization of the GI tract by luminescent EHEC O157:H7 was monitored in real time with a slow-scan charge-coupled device camera. At the same time, fecal shedding of EHEC was studied. Following oral gavage of the La-5 active fraction, we observed a reduced amount of bioluminescence signal along with a decrease in fecal shedding by mice, indicating an effect on the ability of the organism to colonize the GI tract. Our results confirm past evidence of the possibility of blocking or interfering with EHEC's virulence by active molecules contained in the probiotic CFSM and identify novel therapeutic alternatives to antibiotic treatments in the fight against food-borne pathogens.

Entities:  

Mesh:

Year:  2008        PMID: 19088323      PMCID: PMC2643578          DOI: 10.1128/AEM.01651-08

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  36 in total

Review 1.  Quorum sensing by enteric pathogens.

Authors:  Melissa M Kendall; Vanessa Sperandio
Journal:  Curr Opin Gastroenterol       Date:  2007-01       Impact factor: 3.287

2.  Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli.

Authors:  V Sperandio; J L Mellies; W Nguyen; S Shin; J B Kaper
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Decreased adherence of enterohemorrhagic Escherichia coli to HEp-2 cells in the presence of antibodies that recognize the C-terminal region of intimin.

Authors:  L J Gansheroff; M R Wachtel; A D O'Brien
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection.

Authors:  S Tzipori; F Gunzer; M S Donnenberg; L de Montigny; J B Kaper; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice.

Authors:  Quan Shu; Harsharnjit S Gill
Journal:  FEMS Immunol Med Microbiol       Date:  2002-09-06

6.  Probiotics affect virulence-related gene expression in Escherichia coli O157:H7.

Authors:  Maira Jessica Medellin-Peña; Haifeng Wang; Roger Johnson; Sanjeev Anand; Mansel W Griffiths
Journal:  Appl Environ Microbiol       Date:  2007-05-11       Impact factor: 4.792

7.  Inhibition of localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk.

Authors:  A Cravioto; A Tello; H Villafán; J Ruiz; S del Vedovo; J R Neeser
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

8.  Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection.

Authors:  M S Donnenberg; C O Tacket; S P James; G Losonsky; J P Nataro; S S Wasserman; J B Kaper; M M Levine
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

9.  Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study.

Authors:  Kyoto Imase; Akifumi Tanaka; Kengo Tokunaga; Hajime Sugano; Hitoshi Ishida; Shin'ichi Takahashi
Journal:  Kansenshogaku Zasshi       Date:  2007-07

10.  Actin accumulation at sites of bacterial adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic Escherichia coli.

Authors:  S Knutton; T Baldwin; P H Williams; A S McNeish
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

View more
  31 in total

1.  Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice.

Authors:  Kathryn A Eaton; Alexander Honkala; Thomas A Auchtung; Robert A Britton
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 2.  Probiotics, enteric and diarrheal diseases, and global health.

Authors:  Geoffrey A Preidis; Colin Hill; Richard L Guerrant; B S Ramakrishna; Gerald W Tannock; James Versalovic
Journal:  Gastroenterology       Date:  2010-11-12       Impact factor: 22.682

Review 3.  Protective role of gut commensal microbes against intestinal infections.

Authors:  Mi Young Yoon; My Young Yoon; Keehoon Lee; Sang Sun Yoon
Journal:  J Microbiol       Date:  2014-11-29       Impact factor: 3.422

Review 4.  Compositional dynamics of the human intestinal microbiota with aging: implications for health.

Authors:  B Lakshminarayanan; C Stanton; P W O'Toole; R P Ross
Journal:  J Nutr Health Aging       Date:  2014-11       Impact factor: 4.075

5.  Calling all hosts: Bacterial communication in situ.

Authors:  Jessica L Cleary; Alanna R Condren; Katherine E Zink; Laura M Sanchez
Journal:  Chem       Date:  2017-03-09       Impact factor: 22.804

Review 6.  Extracellular vesicles in chronic obstructive pulmonary disease (COPD).

Authors:  Hannah E O'Farrell; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 7.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Fates of acid-resistant and non-acid-resistant Shiga toxin-producing Escherichia coli strains in ruminant digestive contents in the absence and presence of probiotics.

Authors:  Frédérique Chaucheyras-Durand; Fahima Faqir; Aurélie Ameilbonne; Christine Rozand; Christine Martin
Journal:  Appl Environ Microbiol       Date:  2009-11-30       Impact factor: 4.792

Review 9.  Probiotic strains and mechanistic insights for the treatment of type 2 diabetes.

Authors:  Christiane S Hampe; Christian L Roth
Journal:  Endocrine       Date:  2017-10-19       Impact factor: 3.633

Review 10.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.